

Page numbers printed in **boldface type** refer to tables or figures.

A

- Abnormal Involuntary Movement Scale (AIMS), 161
Acamprosate, 211
ACC. *See* Anterior cingulate cortex
Acculturative stress, 56, 114
N-acetylcysteine (NAC), 170-171
ACT (assertive community treatment), 251, 252-256, **253**, 262
Active-phase syndrome, 44-45
Adherence to treatment, 27, 48, 166, 217
Adolescents
 age at onset, 4, 13-14, 35
 cannabis use by, 27, **89**, 91, 118
 cognitive impairment and, 13, 118-119
 diagnostic criteria for, 35
 pathophysiology of schizophrenia in, 86, 94-95, 118-119, 131-132
 psychosocial stressors as risk factor for, 6-7, 117, **119**
Adoption studies, 81
Affective flattening (diminished emotional expression), 40, 42, 149, 218
African Americans
 depressive symptoms among, 217
 quality of mental health care for, 63, 276-277
 schizophrenia prevalence, 62-63
 symptom manifestation, 61
Age. *See* Adolescents; Children; Geriatric patients; Onset; Paternal age
Aggressive behavior (hostility), 149, 153, 158, 168-169, 170
Agitation, 48, 211
Agranulocytosis, 150-151, 153, 167, 170
AIMS (Abnormal Involuntary Movement Scale), 161
Akathisia, 158-159
 antipsychotics with risk of, 156, 157, 161
 defined, 150, 158
 differential diagnosis, 220
 management of, 158-159
 monitoring for, 158
 suicidal behavior and, 158
Akinesia, 218
AKT1 (AKT serine/threonine kinase 1 gene), **89**, 91
Alcohol use. *See* Substance use disorders
Alogia, 40, 42, 149, 218
* α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 92
American Psychiatric Association, 67, 164
Amisulpride, 160, 163, 164-165
Amotivation, 41, 42, 218
Anandamide, 112-113
Anergia, 218
Anhedonia, 40-41, 47, 149, 218
Anterior cingulate cortex (ACC)
 dopamine system and, 135
 neuronal distribution in, 129
 neuronal somal size in, 131
 pathophysiology of, 42, **115**, 116
Antiadrenergic side effects
 antipsychotics with high risk of, 151, **152**, 153, 155, 156, 157
 antipsychotics with low risk of, **152**, 156
Anticholinergic agents, 158-159
Anticholinergic side effects, 151, **152**, 153, 157
Antidepressants, 169
 as adjunctive treatment, 149, 169
 for cocaine use disorder, 210
 for depressive disorders, **206**, 218-219
 for panic disorder, 221
 for posttraumatic stress disorder management, **206**, 224
 for social phobia, **206**
 for tobacco use disorder, 213
Antiepileptic drugs, 149, 169-170
Anti-inflammatory drugs, 172-173
Antipsychotic medications, 150-168. *See also specific drugs*
 adherence to treatment, 27, 48, 166, 217
 adverse effects of, 47, 151, **152**, 153, 158-163. *See also* Antiadrenergic side effects; Anticholinergic side effects; Cardiovascular effects; Diabetes; Extrapyramidal side effects; Prolactin elevation; Weight gain
 for attenuated psychosis, 14
 breast-feeding precautions, 168
 choice of, 96, 164-165
 for co-occurring disorder management, 209-210, 220, 221, 222-223, 226
 course of schizophrenia with, 20-21
 course of schizophrenia without, 15-17, **19**
 cultural variations in prescribing, 63
 development of, 20-23, 150-151, 157-158
 dosage of, **152**, **154**, 165-166
 end state of schizophrenia with, 21-23, **22**, 24
continued on next page

- end state of schizophrenia without, 15, 17-20, **19**, 23, 24
 for first-episode psychosis, 165, 166, 167
 genetic counseling and, 96
 maintenance treatment and relapse prevention with, 28-29, 163-164, 253-254, 258-260
 mechanism of action, 150, 151
 monitoring of, 161, **161**, 253-254
 overview, 149, 150-151, **152**, **154**
 patient education on, 28-29
 polypharmacy, 165, 218
 potency classification, 151-153
 pregnancy precautions, 168
 prognosis of schizophrenia with, 25-26
 response factors, 167
 route of administration, **154**, 166, 210
 targeted, intermittent therapy with, 164
 for treatment-resistant schizophrenia, 153, 167-168, 218
 treatment targets, 166-167
- Anxiety symptoms and disorders, **206**, 220-223
 detection and management of, 221
 management of, 149, 171
 overview, 220-221
 panic attacks and disorders, 221
 prevalence of, 47-48, 220
 in prodromal phase, 14
 psychopathology of, 47-48
 social anxiety disorder, 222-223
- Anxiolytics, 149
- Apathy, 41, 42, 218
- Aripiprazole, **152**, **154**, 156-157
 for cocaine use disorder, 210
 for OCD and OCS management, 226
 prolactin levels and, 163
 weight-gain liability of, 216
- Arsenic, 94
- Asenapine, **152**, 157
- Asians, 56, 62
- Asociality, 40, 218
- Asphyxia, 88
- Assertive community treatment (ACT), 251, 252-256, **253**, 262
- Association studies (genetic), 82
- Astrocyte-related genes, **107**, 108
- Attentional bias, 40
- Attenuated psychosis, 14, 36
- Auditory hallucinations, 38, 39, 56-57, 173-174
- Autoimmune disorders
 depressive symptoms and, 47
 as environmental risk factor, 38, **89-90**, 91-92
- Avolition, 40, 149, 218
- B**
- Basket cells, 132
- BDNF (brain-derived neurotrophic factor), 135-136
- Beads task, 39-40
- Benzodiazepines, 168-169
 for akathisia management, 158-159
 catatonia and, 173
 for neuroleptic malignant syndrome management, 160
 for panic disorder management, 221
 precautions with schizophrenia, 159, 169, 174, 211
- Benztropine, 159
- β -blockers
 for akathisia management, 158-159
 for cardiovascular side effects, 163
- Biases
 of clinicians, 60, 62, 70
 delusions and, 39-40
- Bipolar depression, 46-47
- Bipolar disorder, 45
- Birth risk factors, 6-7, 88, **89-90**, 92
- Birth weight, 88
- Black Caribbeans, 59, 62, 80
- Blacks. *See* African Americans; Black Caribbeans
- Bleuler, Eugen, 15-16, 20, 21, 28
- Bleuler, Manfred, 17-18, 23
- Bleuler's scale, 21
- Blunted affect, 40, 47
- Body/mind control delusions, 37
- Bradykinesia, 41, 150
- Brain-derived neurotrophic factor (BDNF), 135-136
- Breast-feeding, 168
- Brexpiprazole, **152**, 157
- Brief Social Phobia Scale, 222
- Bromocriptine, 159-160
- Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES), 281
- Bupropion, 169, 210, 212, 213-214
- C**
- C4A* and *C4B* (complement component 4 genes), 86
- Calcium channel genes, **85**, 96, 107, **107**
- Calgary Depression Scale for Schizophrenia, 218
- Canadian Psychiatric Association, 188
- Cannabidiol (CBD), 113
- Cannabis use
 adolescents and, 27, **89**, 91, 118
continued on next page

- as co-occurring substance use disorder, 206, 207, 260. *See also* Substance use disorders
- disorganization symptom and, 44
- endocannabinoid models on, 113
- management of, 209, 211
- prevalence of, 49
- prognosis and, 27, 49, 113
- as risk factor, 8-9, 27, 49, **89**, 91
- CAPS (Clinician-Administered PTSD Scale), 223
- Carbamazepine, 169-170
- Cardiovascular effects, **152**, 162-163
- antipsychotics with high risk of, 153, 155, 156, 157
- antipsychotics with low risk of, 153, 157
- hypotension, 151, 153, 155, 157
- management of, 163
- monitoring, **161**, 162-163
- QT prolongation, 156, 157
- Cariprazine, **152**, 157, 210
- CASPR2 (contactin-associated protein-like 2) receptors, 92
- Catatonia, 45, 160, 173
- CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, 50, 151-152
- Causes. *See* Etiology
- CBD (cannabidiol), 113
- CBT. *See* Cognitive behavioral therapy
- CBTp. *See* Cognitive behavioral therapy for psychosis
- CDC42 effector protein (CDC42EP), 130
- Celiac disease, 91
- Cesarean section (emergency), 88
- CFI. *See* DSM-5 Cultural Formulation Interview
- Chandelier cells, 132, 133
- Children
- adoption studies, 81
- age at onset, 35-36
- birth and place of residence as risk factor, 6-7, 92-93
- cognitive symptoms for, 13, 46
- conduct problems during childhood, as risk factor, 50
- diagnostic criteria for, 35-36
- infection and inflammation during childhood, as risk factor, 6, **89-90**, 90-91, **119**
- migration status as risk factor, 117, **119**
- nutrition as risk factor, 117
- pathophysiology of schizophrenia in, 94-95, 111, 117
- premorbid phase of schizophrenia and, 13
- socioeconomic status as risk factor, 59, 92, **119**
- trauma during childhood, as risk factor, 3, 7, **90**, 92, 117, **119**, 223
- twin studies, 81
- Chlorpromazine, 20, 150, 151, **152**
- Chondroitin sulfate proteoglycans [CSPGs], 131
- Choreoathetoid movements. *See* Tardive dyskinesia
- Circuit models, **106**, 113-117, **115**
- for cognitive deficits, 116-117
- for negative symptoms, 116
- for psychosis, 114-116
- CIT (Crisis Intervention Team) mode, 265
- Citalopram, 218
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, 50, 151-152
- Clinician-Administered PTSD Scale (CAPS), 223
- Clinician bias, 60, 62, 70
- Clomipramine, 226
- Clonazepam, 160
- Clozapine, **152**, 153-155
- adverse effects of, 150-151, 153-155, 163, 164, 165, 214
- agranulocytosis risk and, 150-151, 153, 167, 170
- antidepressants and, 169
- contraindications, 165, 167
- ECT and, 173
- efficacy of, 150-151, 153, 164-165
- neuroleptic malignant syndrome incidents and, 160
- for OCD and OCS management, 226
- for social anxiety disorder management, 222
- substance use disorder management, 209-210
- suicidal behavior management with, 153, 220
- for tardive dyskinesia treatment, 160
- for treatment-resistant schizophrenia, 153, 167-168, 218
- Clozapine-refractory schizophrenia, 173
- Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program, 153
- CNS viral infections, 6
- Cocaine use disorder, 48-49, 207, 210. *See also* Substance use disorders
- Coercion, 61-62
- Cognitive behavioral therapy (CBT), 218-219
- for OCS or OCD, 226
- for panic disorder management, 221
- for posttraumatic stress disorder management, 224
- for social anxiety disorder management, 222
- Cognitive behavioral therapy for psychosis (CBTp)
- ABC model of, 186
- description, 186
- goals and treatment principles, 185, 186-187, **187**
- illness management and recovery (IMR) and, 196
- implications for clinical practice, 188
- intervention rationale, 186
- research support, 187-188